Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug 14;12(30):4870-2.
doi: 10.3748/wjg.v12.i30.4870.

Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation

Nobuhisa Akamatsu  1 , Yasuhiko Sugawara, Sumihito Tamura, Yuichi Matsui, Junichi Kaneko, Masatoshi Makuuchi
Affiliations

Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation

Nobuhisa Akamatsu et al. World J Gastroenterol. .

Abstract

Aim: To discuss the use of mycophenolate mofetil (MMF) as an immunosuppressant in steroid resistant rejection after liver transplantation.

Methods: The clinical records of 260 adult patients who underwent living donor liver transplantation (LDLT) were reviewed. Tacrolimus and methylprednisolone were used for primary immunosuppression. Acute rejection was first treated with steroids. When steroid resistance occurred, the patient was treated with a combination of steroids and MMF. Anti-T-cell monoclonal antibody was administered to patients who were not responsive to steroids in combination with MMF.

Results: A total of 90 (35%) patients developed acute rejection. The median interval time from transplantation to the first episode was 15 d. Fifty-four patients were steroid resistant. Forty-four patients were treated with MMF and the remaining 10 required anti-T-cell monoclonal antibody treatment. Progression to chronic rejection was observed in one patient. Bone marrow suppression and gastrointestinal symptoms were the most common side effects associated with MMF use. There was no significant increase in opportunistic infections.

Conclusion: Our results demonstrate that MMF is a potent and safe immunosuppressive agent for rescue therapy in patients with acute rejection after LDLT.

PubMed Disclaimer

References

    1. Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation. 2004;77:S44–S51. - PubMed
    1. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, Gomez Cruz A, Lopez-Monclus J, Sánchez-Turrion V, Lucena Poza JL, Jimenez Garrido M, Millan I. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant. 2004;4:1650–1655. - PubMed
    1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118. - PubMed
    1. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant. 1996;10:140–145. - PubMed
    1. Paterson DL, Singh N, Panebianco A, Wannstedt CF, Wagener MM, Gayowski T, Marino IR. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation. 1998;66:593–598. - PubMed

Publication types